The global antibody drug conjugate market is touted to rise at a CAGR of about 19% during the forecast period of 2017–2023.
Antibody drug conjugates have therapeutic potential but face technical and developmental obstacles. Antibody antibody conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to attack particular cells with the ability of cytotoxic drugs to destroy those cells. Only with increasing technical advances has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the interest of both large and small pharmaceutical companies. Despite the fact that this technology is present in the majority of large pharmaceutical firms, only a few companies have the capability to build ADC. There are several items in the works. The majority of today’s production is done under license agreements.
The global demand for antibody drug conjugates is being driven by advances in medical technology. Furthermore, increasing cancer cases, a rise in the obese population, and an aging population are some of the market’s main driving factors. Furthermore, preclinical research, increased research activities on antibody therapies, increased research on advanced drug discoveries, increased research on oncology diseases, and growing collaboration between research institutes, biopharmaceuticals, and biotechnology companies are fueling the market and are expected to drive the market of antibody drug conjugates in the near future. Increased cancer incidence worldwide, unhealthy urban lifestyles, and increased tobacco and alcohol use across geographies are all significant cancer risk factors.
The global antibody drug conjugate market is segmented on the basis of type, product, technology, application, and end-user.
On the basis of type, the global antibody drug conjugate market is segmented into monoclonal antibodies, linker, drug/toxin, and others.
On the basis of application, the global antibody drug conjugate market is segmented into leukemia, prostate cancer, kidney cancer, pancreas cancer, ovary cancer, glioblastoma, lung cancer, colon cancer, breast cancer, skin cancer, solid tumors, multiple myeloma, lymphoma, and other cancers. The leukemia segment is further divided into Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), and Chronic Lymphocytic Leukemia (CLL).
On the basis of product, the global antibody drug conjugate market is segmented into Adcertis, Kadcyla, and others.
On the basis of technology, the global antibody drug conjugate market is classified into ImmunoGen technology, Seattle Genetics technology, Immunomedics technology, and others.
On the basis of end-user, the global antibody drug conjugate market is classified into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, biopharmaceutical companies, and others.
The global antibody drug conjugate market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.
Because of technological advancements, advancements in production methods, and the contribution of nanotechnology to the development of antibody drug conjugates, the Americas dominated the global antibody drug conjugate market (ADC). Among other nations, such as Mexico, Canada, and others, the United States is the largest market. Despite the fact that many major pharmaceutical companies are working on this technology, the success rate of producing an ADC is very low, and only a few companies have succeeded.
The demand for antibody drug conjugates in Europe is the second highest, followed by Asia Pacific. Governments are putting more emphasis on research and development in order to implement new medicines that can provide the best care for their people.
In the global antibody drug conjugate market, Asia Pacific is a growing market. The antibody drug conjugate market in this area is being driven by increasing consumer awareness and growing government initiatives. There are several items in the works. These advancements are made under the terms of license agreements. Countries such as India and China are considered the fastest growing regions due to the large number of people affected by cancer. They are also willing to implement modern technologies and the latest care options from developed countries in order to improve the quality of life for their citizens.
Some major players in the global antibody drug conjugate market include Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US), and others.